Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vortioxetine EEG study in healthy males
NCT02072278Phase 1Completed
- Sponsor
- Lundbeck
- Start
- Feb 2014
- Primary completion
- Nov 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of vortioxetine in major depressive disorder (MDD) (4 arms), sponsored by Lundbeck. Primary endpoint: Battery of Electroencephalography measurements at Day 3. Started Feb 2014; status: completed.
02
Drugs
vortioxetine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT02072278.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02072278.